ZIOPTAN Drug Patent Profile

Which patents cover Zioptan, and what generic alternatives are available?

Zioptan is a drug marketed by Thea Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-six patent family members in twenty-six countries.

The generic ingredient in ZIOPTAN is tafluprost. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the tafluprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zioptan

A generic version of ZIOPTAN was approved as tafluprost by MICRO LABS on August 19^th, 2019.

Summary for ZIOPTAN

International Patents:	86
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	893
Drug Prices:	Drug price information for ZIOPTAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZIOPTAN
What excipients (inactive ingredients) are in ZIOPTAN?	ZIOPTAN excipients list
DailyMed Link:	ZIOPTAN at DailyMed

See drug prices for ZIOPTAN

Pharmacology for ZIOPTAN

Drug Class	Prostaglandin Analog
Mechanism of Action	Prostaglandin Receptor Agonists
Physiological Effect	Increased Prostaglandin Activity

Paragraph IV (Patent) Challenges for ZIOPTAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZIOPTAN	Ophthalmic Solution	tafluprost	0.0015%	202514	2	2016-02-10

US Patents and Regulatory Information for ZIOPTAN

ZIOPTAN is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	AT	RX	Yes	Yes	10,864,159		Y
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	AT	RX	Yes	Yes	9,999,593		Y

Expired US Patents for ZIOPTAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	5,886,035

International Patents for ZIOPTAN

When does loss-of-exclusivity occur for ZIOPTAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hungary

Japan

Jordan

Lithuania

Malaysia

Mexico

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZIOPTAN around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	071937
Argentina	120961
Australia	2009252210

Supplementary Protection Certificates for ZIOPTAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0850926	CA 2008 00041	Denmark
0850926	300407	Netherlands		300407, 20171222, EXPIRES: 20221221
0850926	SPC/GB09/005	United Kingdom		PRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017

ZIOPTAN (tafluprost ophthalmic solution) market dynamics and financial trajectory: pricing, share, exclusivity, and launch risk

Last updated: July 21, 2026

Executive summary: ZIOPTAN (tafluprost) is a preservative-free prostaglandin analog with a narrow, specialty ophthalmology footprint. Near-term market dynamics are driven by (1) payer and channel mix for drop therapy, (2) substitution pressure from lower-cost prostaglandin competitors and genericized peers, (3) ongoing uptake constraints from dosing inertia and bottle-switch friction, and (4) U.S. patent and regulatory exclusivity boundaries that shape generic entry risk. The product’s financial trajectory in the U.S. is therefore less about “global blockbuster” economics and more about sustained niche share, rebilling behavior under pharmacy benefit management (PBM) formularies, and incremental penetration versus branded prostaglandins and multi-dose generic alternatives.

---

What is ZIOPTAN (tafluprost) and how does it sell in ophthalmology markets?

ZIOPTAN is tafluprost ophthalmic solution (preservative-free prostaglandin analog) administered as an eye drop for reduction of intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension.

Therapeutic and product positioning

• Mechanism: prostaglandin analog class (IOP lowering via uveoscleral outflow).
• Differentiation: preservative-free formulation intended to reduce ocular surface irritation relative to some multi-dose prostaglandin preparations.
• Packaging: uses a single-use style dispensing/containment concept designed to address preservatives, which affects patient and provider preference.

Where ZIOPTAN competes

• Core competitive set: branded and generic prostaglandin analogs (and combination regimens where applicable).
• Typical competitive displacement: payer-driven preferencing toward generics plus clinical comfort with established low-cost prostaglandins.

---

What market dynamics determine ZIOPTAN pricing power and revenue growth?

Short answer: Pricing power is constrained by class substitutability and PBM formulary design; revenue growth depends on maintaining differentiated niche share (tolerability and preservative-free preference) while managing gross-to-net pressure.

Key demand-side dynamics

1. Class substitutability inside ophthalmology

   • Prostanoid drops have similar clinical endpoints for IOP. Substitution economics typically dominate unless a patient demonstrates intolerance or a prescriber prioritizes preservative-free approaches.

2. Payer design and PBM switching

   • ZIOPTAN’s continued uptake is sensitive to formulary placement, prior authorization (PA) rules, step therapy, and copay assistance availability.
   • When PBMs prefer generics, ZIOPTAN’s “switch cost” becomes a financial and operational barrier for adoption.

3. Prescriber inertia and patient adherence

   • Ocular drop therapy adherence can be fragile. Any perception of greater comfort or tolerability can support retention, but bottle/device differences can create early churn.

4. Channel mix

   • Retail pharmacy reimbursement tends to carry higher PBM influence; specialty and buy-and-bill structures are usually less relevant for standard drop therapy.
   • Revenue outcomes hinge on contract rebates and specialty distribution terms.

Key supply-side dynamics

• No broad evidence indicates severe manufacturing scarcity as a primary limiter in the absence of product-specific disruptions.
• The bigger operational driver is cost of goods and ongoing packaging economics relative to generic equivalents.

---

When does ZIOPTAN face exclusivity loss or generic entry risk in the U.S.?

Short answer: Generic entry risk is governed by U.S. Orange Book listings tied to ZIOPTAN’s approved NDA and any patent landscape around the specific formulation, method, and use. The timing determines whether generics can file Paragraph IV certifications and launch immediately upon patent expiration or later after exclusivity.

How to evaluate timing risk for ZIOPTAN

• Identify:
  • Patent expiration dates listed in the Orange Book for tafluprost ophthalmic solution.
  • Any pediatric exclusivity or non-patent exclusivity periods tied to the NDA.
  • Whether any listed patents cover:
    • the formulation/composition,
    • manufacturing/processing,
    • method of use (therapeutic indication),
    • specific dosage form attributes (e.g., preservative-free composition).

What investors and licensors watch

• Whether a “patent fence” blocks Section viii(a) (label) ANDA entry until expiration.
• Whether settlement terms restrict launch dates or impose market-share carve-outs.

Note: The exact U.S. patent and exclusivity calendar depends on Orange Book data and ZIOPTAN’s currently listed patent numbers. This analysis cannot provide a precise date-by-date timeline without those listings.

---

What patents protect tafluprost ophthalmic solution (ZIOPTAN) and how strong is the estate?

Short answer: ZIOPTAN’s practical IP strength is evaluated by (1) how many Orange Book patents remain active for the specific NDA, (2) whether those patents are formulation or method-of-use dependent, and (3) whether ANDA challengers can “design around” composition constraints.

Patent estate elements that matter commercially

• Formulation patents: more difficult for ANDAs to avoid if they must maintain preservative-free attributes and other composition constraints.
• Method-of-use patents: can be avoided by carving indications or using alternative dosing regimens if allowed by label.
• Manufacturing patents: can delay “generic equivalence” if process steps are required and non-infringing variants are not feasible.

How to assess “estate strength”

• Count of enforceable listed patents at the NDA level.
• Remaining claim scope breadth:
  • If core composition claims dominate, design-around options narrow.
  • If claims are narrow, challengers can prevail with similar but non-infringing products.

Note: Precise patent numbers, assignees, and expiration dates for ZIOPTAN require Orange Book and patent docket specifics that are not included in the input.

---

How do Paragraph IV challenges and settlements typically affect ZIOPTAN competitors?

Short answer: The economic impact of Paragraph IV filings is driven less by filing frequency and more by settlement terms: permitted launch dates, exclusivity carve-outs, and licensing fees that change net economics.

What to model in ZIOPTAN’s financial trajectory

• Potential ANDA filers’ likelihood of launching:
  • whether they can obtain approval tied to a non-infringing label,
  • whether they can wait out an injunction or choose at-risk launch.
• Settlement economics:
  • upfront payments,
  • royalties or milestone payments tied to sales,
  • restriction provisions (often “agreed” entry date windows).

Litigation-driven revenue scenarios

• If settlements delay entry, ZIOPTAN’s revenue curve flattens instead of steeply declining.
• If entry occurs earlier than expected, PBM re-contracting often accelerates switching.

---

What is the Orange Book status of ZIOPTAN and how many patents are listed?

Short answer: Orange Book status is the gating variable for generic entry. It determines which product-specific protections are enforceable for the specific tafluprost NDA.

What an Orange Book review should capture

• NDA number for ZIOPTAN.
• Patent list count and categories:
  • composition/formulation,
  • use,
  • manufacturing,
  • dosage form/attributes.
• Expiration dates and any listed pediatric exclusivity add-ons.

Note: Exact Orange Book entries and patent counts cannot be produced without Orange Book data for ZIOPTAN.

---

How does ZIOPTAN compare with competing prostaglandin analogs on financial exposure?

Short answer: ZIOPTAN faces steady pricing pressure because prostaglandin analogs are clinically similar and increasingly commoditized through generics. Its financial resilience depends on payer-specific tolerance and patient switching barriers tied to preservative-free differentiation.

Competitive set archetypes

1. Generic prostaglandin drops

   • Usually lowest unit price and highest PBM adoption likelihood.
   • Financial effect: broad negative pressure on branded niche products unless clear tolerability advantage is documented.

2. Branded prostaglandins

   • If other branded options have better payer contracting, ZIOPTAN’s incremental penetration slows.

3. Combination regimens

   • When patients move to multi-mechanism therapy, monotherapy drop market share can compress.

Where financial trajectory tends to break

• Growth phases:
  • initial adoption in new patients who value preservative-free benefits or have intolerance history.
• Decline phases:
  • after formulary preference shifts or when generics expand penetration in the class.

---

What formulation and device attributes protect ZIOPTAN versus generics?

Short answer: The more ZIOPTAN’s differentiation is embedded in protectable composition and/or critical packaging features, the more it slows generic substitution. If differentiation is mostly commercial (brand + marketing), payer forces can still compress net revenue.

Attributes that typically influence substitution

• Preservative-free composition.
• Specific solution characteristics (solvent system, pH window, stability).
• Container closure system and single-use/tamper features tied to preservative avoidance.

Note: A definitive “protected attributes map” requires mapping of Orange Book formulation claims to the actual ta fluprost product characteristics.

---

Which companies are likely to compete with ZIOPTAN and how does their entry strategy affect revenue?

Short answer: Companies with ANDA portfolios covering prostaglandin analogs and those active in ophthalmic generics are structurally positioned to pressure ZIOPTAN’s pricing once patent barriers soften.

Commercial entry mechanics that matter

• Launch timing:
  • at first allowed approval window, or post-settlement.
• Pricing:
  • typical generics pressure via WAC-to-AWP gap and rebate structures.
• Formularies:
  • PBM contract “dominance” can dictate whether a generic becomes first-line.

Note: Competitor naming and entry probabilities require a patent-challenge landscape and ANDA activity data not provided in the prompt.

---

What revenue exposure does ZIOPTAN face under plausible generic launch scenarios?

Short answer: Revenue risk is concentrated around (1) step-down of differentiated share to generics and (2) gross-to-net deterioration due to rebate and copay tactics needed to sustain volume.

Scenario modeling framework

• Scenario A: delayed entry (settlement or extended patent barriers)
  • Revenue declines more slowly; category share maintained.
• Scenario B: mid-window generic entry
  • Rapid unit decline; revenue compresses with some “retention” among tolerability-seeking patients.
• Scenario C: early entry with broad label/availability match
  • Steeper unit losses, faster PBM switching, larger net revenue erosion.

Note: Without Orange Book timeline and ANDA activity, the analysis cannot assign specific scenario probabilities or dates.

---

Key drivers of net sales trajectory: gross-to-net, contracting, and patient mix

Short answer: For ophthalmology drops, net sales trajectory usually reflects rebate intensity, payer steering, and the proportion of patients eligible for copay assistance.

Net sales mechanics

• Rebates and chargebacks
  • Higher where payer contracts are restrictive or where ZIOPTAN must “buy” share.
• Copay assistance
  • Helps volume but can draw regulator and PBM scrutiny; net impact is heavily contract-dependent.
• PA and step therapy
  • Reduces conversion from Rx to filled scripts when not supported by clinical documentation.

---

How does ZIOPTAN’s financial trajectory compare with other specialty ophthalmology brands?

Short answer: Branded preservative-free or differentiated ophthalmic drops typically show modest growth early and then face nonlinear declines once multiple generic alternatives become formulary-preferred.

What to compare

• Timeline of peak sales vs. competitor generic milestones.
• PBM formulary changes.
• Rate of share loss after first generic entry and subsequent multi-product substitution.

Note: Specific comparative outcomes require numeric financial history for ZIOPTAN and comparable products, which is not included in the input.

---

Key Takeaways

• ZIOPTAN’s financial trajectory is primarily a specialty niche story governed by prostaglandin class substitutability, PBM formularies, and differential patient retention for preservative-free therapy.
• Exclusivity and Orange Book patent scope dictate the timing and magnitude of generic entry risk; revenue curve outcomes depend on whether entry is delayed by patent barriers or settlements.
• Near-term market dynamics are driven by contracting economics (rebates, PA/step therapy) rather than major clinical differentiation at the class level.
• The highest-value diligence for forecasting is an Orange Book and litigation-to-launch mapping that ties patent expiration dates to probable ANDA approvals and settlement launch windows.

---

FAQs

1) What factors most influence ZIOPTAN formulary inclusion by PBMs?
Prostanoid class therapeutics equivalence, payer steering policies (PA/step edits), rebate competitiveness, and evidence or documentation requirements for preservative-free preference.

2) How do prior authorization rules affect ZIOPTAN conversion from prescription to filled scripts?
PA and step therapy can materially reduce fill rates unless prescribers provide qualifying intolerance or medical-necessity documentation aligned with payer criteria.

3) What generic entry pattern is most likely for tafluprost ophthalmic drops?
Typically stepped substitution: first contract-preferred switching within a subset of plans, then broader cross-plan replacement as more products and rebate structures appear.

4) Can preservative-free positioning prevent full erosion after generic entry?
It can reduce patient churn in medically appropriate subsets, but formulary preference and rebate economics usually determine the overall category share trajectory.

5) What litigation outcomes most impact ZIOPTAN’s financial runway?
Settlement terms that delay launch dates, limit label designs, or impose royalty/milestone structures that shift competitor economics.

---

References (APA)

1. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (U.S. FDA).
2. FDA Orange Book patent and exclusivity guidance documents (U.S. FDA).
3. U.S. FDA drug approval and labeling databases (Drugs@FDA).

DrugChatter Q&A for ZIOPTAN

Zioptan preservative free?
Zioptan patient assistance program?
Why is zioptan so expensive?
How much is zioptan without insurance?
Can Zioptan be used as a preservative-free drop?